"Boswellia is good for joints." You've probably heard it, and it's true. But the word "Boswellia" on a label tells you surprisingly little about whether that product will do anything.
What Boswellia Is
Boswellia serrata, known in India as shallaki or salai guggul, is a tree resin used in Ayurveda for centuries. Modern research has identified the compounds behind its effects: a group called boswellic acids. The one researchers focus on most is AKBA (acetyl-11-keto-beta-boswellic acid).
AKBA inhibits an enzyme called 5-LOX (5-lipoxygenase), which produces inflammatory molecules involved in joint pain and swelling. Common painkillers like ibuprofen work on a different pathway (COX), which is one reason boswellia is studied as a separate approach.
Why the Big Number Misleads
Two labels can both say "Boswellia" and deliver very different amounts of the compounds that matter:
-
Standard extracts contain only a few percent AKBA. Laboratory analyses of typical Boswellia serrata extracts have measured AKBA at around 3 to 4%. So most of a "400mg" capsule is not AKBA.
-
"65% boswellic acids" is a total, not the active. That figure adds up several boswellic acids, most far weaker than AKBA. It doesn't tell you how much AKBA is inside.
-
Market products vary widely. Researchers who tested commercial boswellia products have found large differences in actual boswellic acid content, and some label claims that don't hold up.
A bigger milligram number isn't a stronger product. What matters is which extract, standardised to what, at the dose that was studied.
Why Branded, Standardised Extracts Matter
Clinical trials don't test "boswellia" in general. They test a specific extract, made a specific way, at a specific dose. Branded extracts such as Aflapin® and 5-Loxin® are standardised so that every batch matches the material that was studied.
RCT
Aflapin vs placebo, 30 days (2011)
60 adults with knee osteoarthritis took 100mg of Aflapin or placebo daily. The Aflapin group improved significantly in pain and physical function, with improvement recorded from day 5 (Vishal et al., Int J Med Sci).
RCT
Aflapin vs 5-Loxin vs placebo, 90 days (2010)
60 adults with knee osteoarthritis. Both extracts at 100mg a day improved pain and function compared with placebo, with improvement from day 7 in the Aflapin group.
RCT
Aflapin vs placebo, 30 days (2023)
70 adults with knee osteoarthritis at 100mg a day, with significant improvement in pain scores from day 5 (Karlapudi et al.).
These are small, industry-funded studies, which is typical for branded ingredients. But they test the exact material and dose, which generic boswellia can't claim.
How to Read a Boswellia Label
✓
Look for a named extract (such as Aflapin or 5-Loxin) or a stated AKBA percentage.
✓
Check the dose matches the research for that extract. For Aflapin, that's 100mg a day.
✓
Be wary of "boswellia extract" with no detail, or only a "65% boswellic acids" claim.
✓
Remember it targets inflammation only. It doesn't address cartilage or joint fluid on its own.
Is Boswellia Safe?
In the published trials, boswellia extracts were generally well tolerated, with mild stomach upset the most common complaint. As with any supplement, check with a doctor first if you're pregnant, breastfeeding, on blood thinners or other regular medication, or have a medical condition.
Frequently Asked Questions
Does boswellia work for knee pain?
Several randomised, placebo-controlled trials of standardised boswellia extracts have found improvements in knee osteoarthritis pain and function. Results depend heavily on the specific extract and dose.
How long does boswellia take to work?
In the Aflapin trials, improvements were recorded from around day 5 to day 7, continuing over the following weeks.
Is shallaki the same as boswellia?
Yes, shallaki and salai guggul are traditional names for Boswellia serrata. Traditional powders are not standardised, so their AKBA content is unknown.
Can I take boswellia with painkillers?
Ask your doctor. Both can affect the stomach, and your doctor will know your other medicines.
This article is for education only and is not medical advice. Speak to a doctor before starting any supplement.

About the author
Harshit Kansal
Founder, HUMYN Health · Chartered Accountant
Harshit is the founder of HUMYN Health and a Chartered Accountant. Both of his parents live with knee osteoarthritis, which led him to spend months reading the clinical research on joint-health ingredients before building HUMYN.
He writes about how to read supplement labels, what the published evidence actually says, and how to look after joints as we age. His articles are educational and not medical advice.
Follow on LinkedIn →